Thromb Haemost 1992; 67(01): 117-120
DOI: 10.1055/s-0038-1648391
Original Articles
Schattauer GmbH Stuttgart

No Evidence for Short-Term Regulation of Plasminogen Activator Inhibitor Activity by Insulin in Man

Helena Vuorinen-Markkola
The Second Department of Medicine, Helsinki University, Helsinki, Finland
,
llpo Puhakainen
The Second Department of Medicine, Helsinki University, Helsinki, Finland
,
Hannele Yki-Järvinen
The Second Department of Medicine, Helsinki University, Helsinki, Finland
› Author Affiliations
Further Information

Publication History

Received 03 May 1991

Accepted after revision 26 July 1991

Publication Date:
02 July 2018 (online)

Summary

In crossectional studies a positive correlation has been found between circulating insulin, triglycerides and plasminogen activator inhibitor (PAI-1) activity. To directly examine the effect of insulin on PAI-1 activity in vivo, we determined the response of PAI-1 activity in 17 normal subjects to acute hyperinsulinemia (serum free insulin 92 ± 8 mU/l) during maintenance of normoglycemia (plasma glucose 5.1 ± 0.1 mmol/l). In 12 matched control subjects PAI-1 activity was measured during infusion of saline (serum free insulin 3.6 ± 0.3 mU/l, plasma glucose 5.2 ± 0.1 mmol/l). Plasma PAI-1 activity decreased during the insulin infusion from 9.0 α 1.4 to 5.6 α 0.8 U/ml (p <0.01), and during saline infusion from 7.0 ± 1.4 to 4.3 ± 0.6 U/ml (p <0.05). Serum triglyceride concentrations decreased from 1.09 ± 0.20 to 0.76 ± 0.09 mmol/l (p < 0.001) during hyperinsulinemia but remained unchanged during the saline infusion (1.04 ± 0.11 vs. 1.02 ± 0.12 mmol/l, NS). We conclude that insulin does not acutely change plasma PAI-1 activity, and that acute insulin-induced changes in serum triglycerides occur independently from those of PAI-1 activity.

 
  • References

  • 1 Kruithof EKO, Tran-Thang C, Bachmann F. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemostas 1986; 55: 65-69
  • 2 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 25: 1557-1563
  • 3 Landin K, Tengbom L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227: 273-278
  • 4 Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35 (03) 250-253
  • 5 Auwerx J, Bouillon R, Collen D, Gebores J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8 (01) 68-72
  • 6 Ferrannini E, Haffner SM, Stern MP. Essential hypertension: an insulin-resistant state. J Cardiovasc Pharmacol 1990; 15 (Supp) (15) S18-S25
  • 7 Modan M, Halkin H, Almong S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z. Hyperinsulinemia, a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-817
  • 8 Nikkilä E, Vesenne R, Miettinen T, Pelkonen R. Plasma-insulin in coronary heart-disease. Lancet 1965; 2: 508-511
  • 9 Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemostas 1988; 60: 491-494
  • 10 Kooistra T, Bosma PJ, Tons HA, van den Berg AP, Meyer P, Princen HM. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemostas 1989; 62: 723-728
  • 11 Landin K, Tengbom L, Chmielewska J, von Schenck H, Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemostas 1991; >65 (02) 130-133
  • 12 Grant PJ, Kruithof EKO, Felley CP, Felber JP, Bachmann F. Shortterm infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sei 1990; 79: 513-516
  • 13 Potter van Loon BJ, de Bart ACW, Radder JK, Frölich M, Kluft C, Meinders AE. Acute exogenous hyperinsulinemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans. Fibrinolysis 1990; 4 (Supp) (12) 93-94
  • 14 Andreotti F, Davies GJ, Hackett D, Khan MI, de Bart A. Dooi-jewaard G, Maseri A, Kluft C. Cicardian variation of fibrinolytic factors in normal human plasma. Fibrinolysis 1988; 2 (Supp) (12) 90-92
  • 15 Kluft C, Jie AFH, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemostas 1988; 59: 329-332
  • 16 Kluft C, Andreotti F. Consequences of the cicardian fluctuation in plasminogen activator inhibitor 1 (PAI-1) for studies on blood fibrinolysis. Fibrinolysis 1988; 2 (Supp) (12) 93-95
  • 17 Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79: 101-106
  • 18 Takada A, Takada Y, Urano T, Sakakibara K, Rydzewski A. Fluctuations of euglobulin lysis time, tissue plasminogen activator, and free and total plasminogen activator inhibitor levels in plasma daytime. Thromb Res 1990; 57: 13-20
  • 19 Chandler WL, Momin D, Whitten RO, Angleton P, Farin FM, Fritsche TR, Veith RC, Stratton JR. Insulin, cortisol and catecholamines do not regulate cicardian variation in fibrinolytic activity. Thromb Res 1990; 58: 1-12
  • 20 DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-23
  • 21 Yki-Järvinen H, Young AA, Lamkin C, Foley JE. Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest 1987; 79: 1713-1719
  • 22 Kadish AH, Little RL, Sternberg JC. A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin Chem 1968; 14: 116-131
  • 23 Gennaro WD, Van Norman JD. Quantitation of free, total and antibody-bound insulin in insulin treated diabetics. Clin Chem 1975; 21: 873-879
  • 24 Wahlefeld AW. Triglyceride determination after enzymatic hydrolysis. In: Methods of Enzymatic Analysis. Bermeyer HV. (ed). Academic Press; New York: 2nd ed. 1974. pp 1831-1835
  • 25 Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH. Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes 1977; 26: 22-29
  • 26 Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131-141
  • 27 Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154-160
  • 28 Ducimetiere P, Eschwege R, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980; 19: 205-210
  • 29 Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, Serradimigni A, Collen D. Plasma plasminogen activator inhibitor-1 in angina pectoris: influence of plasma insulin and acute-phase response. Arteriosclerosis 1989; 9: 362-367
  • 30 Kelley D, Mitrakou A, Marsh H, Schwenk F, Benn J, Sonnenberg G, Arcangeli M, Aoki T, Sorensen J, Berger M, Sonksen P, Gerich J. Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. J Clin Invest 1988; 81: 1563-1571
  • 31 Sundell BI, Nilsson TK, Hallmans G, Hellsten G, Dahlen G. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a North Swedish population. Atherosclerosis 1989; 80: 9-16
  • 32 Crutchley DJ, McPhee GV, Terris MF, Canossa-Terris MA. Levels of the hemostatic factors in regulation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator and type 1 plasminogen activator inhibitor. Arteriosclerosis 1989; 9: 934-939
  • 33 Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin. Thromb Haemostas 1989; 61: 370-373
  • 34 Frade GLJ, de la Calle H, Torrado MC, Lara JI, Cuellar L, Avello GA. Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus. Thromb Res 1990; 59: 51-59
  • 35 Kokolis N, Ploumis Th, Smokovitis A. The effect of experimental chronic hypertension on tissue plasminogen activator activity, plasminogen activator inhibition and plasmin inhibition. Thromb Res 1989; 56: 523-528